Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05187832 · ClinicalTrials.gov registry record · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
A Phase 1 study of Advanced or Metastatic Breast Cancer, sponsored by Kind Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT05187832: Recruiting Phase 1 study of Advanced or Metastatic Breast Cancer, sponsored by Kind Pharmaceuticals.
NCT05187832 is a Phase 1 study of Advanced or Metastatic Breast Cancer that is actively recruiting participants, run by Kind Pharmaceuticals. The registered enrollment target is 61 participants, below the 404-participant average among 3 other Advanced or Metastatic Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05187832, a Phase 1 study of Advanced or Metastatic Breast Cancer, is actively recruiting participants, sponsored by Kind Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \[HER2\]-negative) breast cancer.
Primary Outcome
Number of participants with adverse events
Conditions Studied
Interventions
- DRUG AND019 PO QD
Study Locations (1)
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What NCT05187832 shows while recruiting
NCT05187832 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 404-participant average among 3 other Advanced or Metastatic Breast Cancer trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Advanced or Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AND019 PO QD is the first listed.
NCT05187832 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05187832 about?
NCT05187832 is a clinical study titled "A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer". This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal g...
What is the current status of trial NCT05187832?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2022-10-05. Estimated completion is 2026-11.
What conditions does trial NCT05187832 study?
This clinical trial studies the following conditions: Advanced or Metastatic Breast Cancer.
What interventions are being tested in trial NCT05187832?
The interventions under investigation include: AND019 PO QD (DRUG).
Who is sponsoring clinical trial NCT05187832?
This trial is sponsored by Kind Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05187832 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
COMPLETED · Phase 1
-
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
- NCT05593653 · 61 participants · Phase 4
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI